Skip to main content
. 2011 Oct 5;50(12):2223–2232. doi: 10.1093/rheumatology/ker253

Fig. 4.

Fig. 4.

Mean pre-course baseline DAS-28-ESR by course of rituximab (a) and patients with an increase in DAS-28-ESR of 1.2 above the lowest DAS-28-ESR within the course (b). P < 0.001, t-test of change in DAS-28-ESR, within groups (a). †P < 0.001, Pearson’s chi-square between group difference (b).